NCT01155791
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer treatment 1 terminated NCT04262154
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer treatment 2 active_not_recruiting NCT03763851
Cannabis Oil and Radiation Therapy for the Management of Pain No drug interventions treatment 2 terminated NCT04556045
Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer No drug interventions supportive_care Not Available recruiting NCT01303705
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer treatment 1 completed NCT04220983
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer No drug interventions treatment Not Available completed NCT05896371
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy treatment 1 / 2 not_yet_recruiting NCT04846478
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC treatment 1 active_not_recruiting NCT03110588
Phase I Trial of PACE for Metastatic Prostate Cancer treatment 1 withdrawn NCT05885009
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) No drug interventions Not Available Not Available recruiting NCT04400656
PROState Pathway Embedded Comparative Trial No drug interventions Not Available Not Available completed NCT06177015
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC treatment 3 recruiting NCT01815515
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer diagnostic 1 / 2 completed NCT02655952
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients treatment 1 completed NCT04746300
imPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS No drug interventions Not Available Not Available recruiting NCT05167175
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation treatment 2 recruiting NCT00439270
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer treatment 1 / 2 completed NCT06009549
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients No drug interventions Not Available Not Available not_yet_recruiting NCT03432949
Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC treatment 4 active_not_recruiting NCT01957436
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer treatment 3 active_not_recruiting NCT06303713
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer treatment 1 recruiting NCT05751941
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer treatment 2 recruiting NCT01012141
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer treatment 2 completed NCT03554317
COMbination of Bipolar Androgen Therapy and Nivolumab treatment 2 completed NCT02206724
Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer No drug interventions treatment Not Available withdrawn NCT04330716
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers No drug interventions health_services_research Not Available completed NCT05404139
Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) treatment 2 active_not_recruiting NCT06050239
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer treatment 0 recruiting NCT01981122
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer basic_science 2 completed NCT06040125
Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial No drug interventions supportive_care Not Available recruiting NCT06350825
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients No drug interventions treatment 3 recruiting NCT04026230
Impact of Atorvastatin on Prostate Cancer Progression During ADT treatment 3 recruiting NCT04925648
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction treatment 2 recruiting NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC treatment 1 / 2 recruiting NCT04086966
PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study No drug interventions diagnostic 1 completed NCT03050866
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) diagnostic 2 unknown_status NCT05800665
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer No drug interventions treatment 1 recruiting NCT05717582
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment treatment 2 not_yet_recruiting NCT03073473
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers No drug interventions Not Available Not Available terminated NCT05471427
Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer Not Available Not Available completed NCT02151760
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer diagnostic 1 completed NCT02036060
Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. treatment 2 completed NCT04085991
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer No drug interventions treatment 2 terminated NCT06267729
Study of AZD0754 in Participants With Metastatic Prostate Cancer No drug interventions treatment 1 / 2 recruiting NCT06566989
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) treatment 1 not_yet_recruiting NCT05367440
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer treatment 1 / 2 recruiting NCT03764540
Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide treatment 2 active_not_recruiting NCT03181867
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer diagnostic 2 enrolling_by_invitation NCT05156372
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients No drug interventions treatment Not Available withdrawn NCT06516510
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer other 0 not_yet_recruiting NCT02963155
Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration No drug interventions basic_science Not Available unknown_status NCT04926155
The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer treatment 2 unknown_status NCT01560923
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer treatment 2 completed NCT02730338
INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4) No drug interventions treatment Not Available active_not_recruiting NCT03072238
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer treatment 3 completed NCT00494338
Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer treatment 2 terminated NCT01062503
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC Not Available Not Available completed NCT06112990
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression No drug interventions treatment 3 recruiting NCT02049190
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer treatment 1 / 2 unknown_status NCT04179864
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer treatment 1 / 2 active_not_recruiting NCT03934164
Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO No drug interventions Not Available Not Available recruiting NCT06359821
Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer No drug interventions other 0 enrolling_by_invitation NCT02962284
One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ treatment 2 completed NCT00452387
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) treatment 2 terminated NCT02744287
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors treatment 1 / 2 suspended NCT06479187
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer diagnostic 4 not_yet_recruiting NCT05415787
Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer. No drug interventions Not Available Not Available completed NCT04726033
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) No drug interventions treatment 0 completed NCT00003533
Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer treatment 2 terminated NCT04876651
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only No drug interventions treatment 3 recruiting NCT03763253
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms No drug interventions treatment 2 recruiting NCT03497377
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer. diagnostic 1 completed NCT04786847
177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study treatment 1 completed NCT06062745
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT diagnostic 1 recruiting NCT03493945
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) treatment 1 / 2 active_not_recruiting NCT01677897
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients treatment 2 completed NCT04545697
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer No drug interventions health_services_research Not Available completed NCT05983783
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC treatment 3 recruiting NCT05011383
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers treatment 2 recruiting NCT02066961
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer No drug interventions Not Available Not Available completed NCT06582628
Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) treatment 2 recruiting NCT05590793
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate treatment 3 completed NCT00441571
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer treatment 1 unknown_status NCT04031378
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer No drug interventions treatment 2 unknown_status NCT00942578
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer treatment 2 completed NCT04070209
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) treatment 2 recruiting NCT05617885
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer treatment 1 / 2 active_not_recruiting NCT03248570
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects treatment 2 completed NCT04528199
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer No drug interventions diagnostic 1 terminated NCT04887506
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer treatment 3 completed NCT06429813
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006) No drug interventions supportive_care Not Available recruiting NCT01153113
Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines No drug interventions treatment 1 / 2 withdrawn NCT04067713
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer No drug interventions Not Available Not Available recruiting NCT00599313
Phase II Sunitinib Prog Met AIPC treatment 2 completed NCT02051218
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks supportive_care 3 active_not_recruiting NCT01558219
Second-line Chemotherapy in Castration Resistant Prostate Cancer No drug interventions treatment 2 completed NCT04951817
68Ga-PSMA PET/CT for Ra223 Assessment No drug interventions diagnostic Not Available recruiting NCT02260817
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer diagnostic 3 completed NCT04446117
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC treatment 3 active_not_recruiting NCT03173924
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer diagnostic 2 active_not_recruiting NCT03871816
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer No drug interventions Not Available Not Available completed NCT05771896
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC treatment 3 withdrawn NCT04533958
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy No drug interventions supportive_care Not Available unknown_status NCT04925063
The Effect of Metformin in Patients With Newly Diagnosed mHSPC treatment 2 not_yet_recruiting NCT01933022
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease other 4 terminated NCT03143322
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases No drug interventions treatment Not Available recruiting NCT06439225
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes treatment 3 not_yet_recruiting NCT06329830
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer treatment 1 / 2 not_yet_recruiting NCT04193657
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC No drug interventions Not Available Not Available completed NCT01233557
Biomarkers of Bone Resorption in Metastatic Prostate Cancer No drug interventions Not Available Not Available completed NCT03867357
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia Not Available Not Available completed NCT02380274
Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) No drug interventions Not Available Not Available completed NCT04335682
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide other 2 recruiting NCT05796973
Measuring Oncological Value of Exercise and Statin treatment 3 recruiting NCT01923727
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer No drug interventions diagnostic 1 / 2 completed NCT05933876
The Impact of Radiotherapy on Oligometastatic Cancer No drug interventions Not Available Not Available recruiting NCT04709276
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer treatment 2 recruiting NCT00216060
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy prevention 3 terminated NCT00213694
PROSTACOX : Metastatic Prostate Chemotherapy Not Available Not Available completed NCT03939689
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone treatment 2 active_not_recruiting NCT04787744
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer treatment 2 / 3 recruiting NCT04332744
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) treatment 2 active_not_recruiting NCT02500901
Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) treatment 1 terminated NCT05582772
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer No drug interventions supportive_care Not Available recruiting NCT00255268
CMAB vs IMAB in Metastatic Prostate Cancer treatment 4 withdrawn NCT03977610
The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy No drug interventions diagnostic Not Available completed NCT00541281
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer treatment 2 completed NCT03585114
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers treatment 2 active_not_recruiting NCT02278055
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer supportive_care 2 completed NCT01814150
The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel No drug interventions Not Available Not Available unknown_status NCT05127850
MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer No drug interventions health_services_research Not Available completed NCT04030338
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer No drug interventions Not Available Not Available active_not_recruiting NCT05413421
Study of ORIC-944 in Patients With Metastatic Prostate Cancer No drug interventions treatment 1 recruiting NCT00923221
Collection of Blood From Patients With Prostate Cancer No drug interventions Not Available Not Available recruiting NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT00415779
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer treatment 1 completed NCT03673787
A Trial of Ipatasertib in Combination With Atezolizumab health_services_research 1 / 2 unknown_status NCT04603833
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC treatment 2 unknown_status NCT02407054
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer treatment 2 completed NCT05078151
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer No drug interventions diagnostic Not Available unknown_status NCT01718353
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment 2 completed NCT03223597
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223 Not Available Not Available completed NCT04983628
Molecular Profiling in Prostate Cancer No drug interventions Not Available Not Available unknown_status NCT02825628
Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) No drug interventions treatment 2 completed NCT06141993
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials No drug interventions Not Available Not Available recruiting NCT05627778
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis diagnostic 1 / 2 unknown_status NCT05679388
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients treatment 1 recruiting NCT04028388
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer treatment 2 completed NCT05361915
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer treatment 2 suspended NCT03414437
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303) No drug interventions Not Available Not Available unknown_status NCT02074137
Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer treatment 4 completed NCT04824937
Telaglenastat + Talazoparib In Prostate Cancer treatment 2 unknown_status NCT04116775
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer. treatment 2 unknown_status NCT02105675
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer treatment 2 completed NCT02378870
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC No drug interventions treatment 2 terminated NCT03089099
Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer No drug interventions Not Available Not Available unknown_status NCT05457699
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate) No drug interventions treatment 2 recruiting NCT04452136
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer Not Available Not Available approved_for_marketing NCT03843918
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer treatment 1 / 2 suspended NCT01428219
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone treatment 2 terminated NCT03569241
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases No drug interventions treatment 2 active_not_recruiting NCT04833517
Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) No drug interventions Not Available Not Available recruiting NCT03761017
MGD019 DART® Protein in Unresectable/Metastatic Cancer treatment 1 active_not_recruiting NCT04660617
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA) No drug interventions Not Available Not Available unknown_status NCT06136624
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) treatment 3 recruiting NCT03024216
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer treatment 1 completed NCT05563558
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) treatment 2 recruiting NCT03434158
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) treatment 2 completed NCT01487863
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer basic_science 2 completed NCT03655886
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial No drug interventions treatment 2 recruiting NCT03696186
Selective Treatment According to Molecular Subtype of Prostate Cancer treatment 2 unknown_status NCT03129139
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors treatment 1 recruiting NCT03775525
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer treatment 1 active_not_recruiting NCT05283330
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors No drug interventions treatment 1 recruiting NCT06450548
Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA No drug interventions other Not Available not_yet_recruiting NCT02961257
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel treatment 3 completed NCT05002465
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer Not Available Not Available no_longer_available NCT03295565
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel treatment 2 / 3 completed NCT04781374
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 withdrawn NCT03951831
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer treatment 2 active_not_recruiting NCT03223727
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223 No drug interventions Not Available Not Available completed NCT05000827
Dutch National Randomized Study: PSMA-PET/CT as a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients No drug interventions diagnostic Not Available recruiting NCT04590976
Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research No drug interventions Not Available Not Available completed NCT05570994
177Lu-HTK03170 in mCRPC With PSMA Positive Disease treatment 1 / 2 recruiting NCT02485691
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent treatment 4 completed NCT03646162
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer No drug interventions treatment 2 completed NCT05242744
FTT PET/CT in Metastatic Prostate Cancer No drug interventions Not Available Not Available recruiting NCT05067140
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer treatment 1 / 2 recruiting NCT06320067
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer treatment 3 recruiting NCT02933801
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. treatment 2 terminated NCT04483414
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer No drug interventions diagnostic 2 withdrawn NCT03878823
Safety and Pharmacokinetics of ODM-209 No drug interventions treatment 1 / 2 completed NCT03494803
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC No drug interventions Not Available Not Available withdrawn NCT01322490
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer No drug interventions treatment 3 completed NCT03833921
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer treatment 2 recruiting NCT05384002
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum No drug interventions Not Available Not Available recruiting NCT01595087
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) No drug interventions treatment 1 / 2 completed NCT02815033
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide treatment 2 completed NCT03129854
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa) No drug interventions treatment Not Available recruiting NCT06430411
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study Not Available Not Available not_yet_recruiting NCT05352178
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer No drug interventions treatment 3 recruiting NCT04641078
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer treatment 2 recruiting NCT02964988
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer No drug interventions diagnostic 2 terminated NCT03436485
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer treatment 1 / 2 active_not_recruiting NCT05655715
Checkpoint Inhibitors and SBRT for mCRPC treatment 2 recruiting NCT04848337
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer treatment 2 recruiting NCT03490032
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) No drug interventions diagnostic 1 / 2 completed NCT03362359
Ga-68-PSMA-11 in High-risk Prostate Cancer No drug interventions diagnostic 1 / 2 completed NCT05567770
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer treatment 1 withdrawn NCT05177042
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) treatment 1 active_not_recruiting NCT03693742
MSG Use With 18F-DCFPyL PET/CT Imaging No drug interventions diagnostic Not Available completed NCT04916613
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) treatment 3 recruiting NCT03575819
A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) No drug interventions treatment 1 completed NCT06242119
Clinical Application of the J-PET Scanner Prototype No drug interventions Not Available Not Available recruiting NCT02913196
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC treatment 1 active_not_recruiting NCT03658486
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial No drug interventions other Not Available completed NCT03988686
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone No drug interventions treatment Not Available unknown_status NCT06171139
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer No drug interventions health_services_research Not Available recruiting NCT05553639
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 1 / 2 terminated NCT05327465
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy No drug interventions supportive_care Not Available recruiting NCT03396874
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence diagnostic 2 completed NCT04019327
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer treatment 1 / 2 active_not_recruiting NCT04776889
The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients treatment 4 completed NCT06461689
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer Not Available Not Available not_yet_recruiting NCT05276492
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. treatment 1 active_not_recruiting NCT06251492
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) treatment 2 recruiting NCT01360840
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer treatment 2 completed NCT02814968
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide treatment 2 completed NCT04179968
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer No drug interventions diagnostic 2 completed NCT03888612
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer treatment 1 / 2 active_not_recruiting NCT06260410
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics No drug interventions Not Available Not Available recruiting NCT06496581
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) treatment 3 not_yet_recruiting NCT03507595
Evaluation of the Metastasis and Recurrence of Prostate Cancer No drug interventions Not Available Not Available unknown_status NCT03413995
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations treatment 2 active_not_recruiting NCT04983095
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer No drug interventions treatment 3 recruiting NCT05530395
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC No drug interventions Not Available Not Available not_yet_recruiting NCT03850795
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) treatment 3 terminated NCT03784755
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer No drug interventions treatment Not Available recruiting NCT06215508
Geriatric Assessment and Technology Evaluation in Prostate Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT04086290
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients No drug interventions treatment 1 / 2 recruiting NCT02379390
Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide treatment 2 terminated NCT06165302
Exercise in Prostate Cancer No drug interventions other Not Available not_yet_recruiting NCT03739684
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer diagnostic 3 completed NCT01254279
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen treatment 3 completed